全文获取类型
收费全文 | 170392篇 |
免费 | 6782篇 |
国内免费 | 314篇 |
专业分类
耳鼻咽喉 | 3062篇 |
儿科学 | 6394篇 |
妇产科学 | 4372篇 |
基础医学 | 24010篇 |
口腔科学 | 4796篇 |
临床医学 | 12724篇 |
内科学 | 31009篇 |
皮肤病学 | 4676篇 |
神经病学 | 15706篇 |
特种医学 | 8777篇 |
外国民族医学 | 24篇 |
外科学 | 28319篇 |
综合类 | 1090篇 |
一般理论 | 37篇 |
预防医学 | 7980篇 |
眼科学 | 4603篇 |
药学 | 11795篇 |
中国医学 | 348篇 |
肿瘤学 | 7766篇 |
出版年
2023年 | 774篇 |
2021年 | 1235篇 |
2020年 | 1110篇 |
2019年 | 1298篇 |
2018年 | 2875篇 |
2017年 | 2366篇 |
2016年 | 3301篇 |
2015年 | 3658篇 |
2014年 | 3872篇 |
2013年 | 5429篇 |
2012年 | 8319篇 |
2011年 | 7716篇 |
2010年 | 4613篇 |
2009年 | 3670篇 |
2008年 | 7656篇 |
2007年 | 8491篇 |
2006年 | 8540篇 |
2005年 | 8934篇 |
2004年 | 8502篇 |
2003年 | 8416篇 |
2002年 | 8303篇 |
2001年 | 6183篇 |
2000年 | 6250篇 |
1999年 | 5407篇 |
1998年 | 1586篇 |
1997年 | 1305篇 |
1996年 | 999篇 |
1995年 | 806篇 |
1994年 | 748篇 |
1992年 | 2393篇 |
1991年 | 2316篇 |
1990年 | 2278篇 |
1989年 | 2125篇 |
1988年 | 1858篇 |
1987年 | 1844篇 |
1986年 | 1708篇 |
1985年 | 1647篇 |
1984年 | 1284篇 |
1983年 | 1023篇 |
1979年 | 1382篇 |
1978年 | 1017篇 |
1977年 | 852篇 |
1975年 | 1088篇 |
1974年 | 1131篇 |
1973年 | 1018篇 |
1972年 | 1033篇 |
1971年 | 1002篇 |
1970年 | 887篇 |
1969年 | 833篇 |
1968年 | 802篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
251.
OLG Düsseldorf 《MedR Medizinrecht》2005,23(9):528-530
Abstrakt 1. Die Abgabe von Hilfsmitteln innerhalb einer Arztpraxis ist durch x 4 Nr. 11 UWG (n. F.) i. V. mit x 3 Abs. 2 BO nicht von
vornherein ausgeschlossen, wenn dies aus medizinischen Gründen geschieht.
2. Ein etwaiger Versto? gegen sozialversicherungsrechtliche Vorschriften kann nicht als wettbewerbsrechtlich unlauter beurteilt
werden; sozialversicherungsrechtliche Normen sind einer wettbewerbsrechtlichen Beurteilung entzogen. 相似文献
252.
Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. 总被引:5,自引:0,他引:5
Ambros J Beer Roland Haubner Michael Goebel Stephan Luderschmidt Mary E Spilker Hans-Jürgen Wester Wolfgang A Weber Markus Schwaiger 《Journal of nuclear medicine》2005,46(8):1333-1341
(18)F-Galacto-RGD has been developed for PET of alpha(v)beta(3) integrin expression, a receptor involved in, for example, angiogenesis and metastasis. Our aim was to study the kinetics and biodistribution of (18)F-Galacto-RGD in cancer patients. METHODS: Nineteen patients with metastases of malignant melanoma (n = 7), sarcomas (n = 10), or osseous metastases (n = 2) were examined. After injection of 133-200 MBq (18)F-Galacto-RGD, 3 consecutive emission scans from the pelvis to the thorax or dynamic emission scans of the tumor over 60 min, followed by 1 static emission scan of the body, were acquired. Time-activity curves and standardized uptake values (SUVs) were derived by image region-of-interest analysis with image-based arterial input functions. Compartmental modeling was used to derive the distribution volume for muscle tissue and tumors. RESULTS: (18)F-Galacto-RGD showed rapid blood clearance and primarily renal excretion. SUVs in tumors ranged from 1.2 to 9.0. Tumor-to-blood and tumor-to-muscle ratios increased over time, with peak ratios of 3.1 +/- 2.0 and 7.7 +/- 4.3, respectively, at 72 min. The tumor kinetics were consistent with a 2-tissue compartment model with reversible specific binding. Distribution volume values were, on average, 4 times higher for tumor tissue (1.5 +/- 0.8) than those for muscle tissue (0.4 +/- 0.1). The data suggest that there was only minimal free and bound (specific or nonspecific) tracer in muscle tissue. CONCLUSION: (18)F-Galacto-RGD demonstrates a highly favorable biodistribution in humans with specific receptor binding. Most important, this study shows that (18)F-Galacto-RGD allows visualization of alpha(v)beta(3) expression in tumors with high contrast. Consequently, this tracer offers a new strategy for noninvasive monitoring of molecular processes and may supply helpful information for planning and controlling of therapeutic approaches targeting the alpha(v)beta(3) integrin. 相似文献
253.
Monitoring left ventricular dilation in mice with PET. 总被引:3,自引:0,他引:3
Lars Stegger Klaus P Sch?fers Ulrich Fl?gel Lefteris Livieratos Sven Hermann Christoph Jacoby Petra Keul Edward M Conway Otmar Schober Jürgen Schrader Bodo Levkau Michael Sch?fers 《Journal of nuclear medicine》2005,46(9):1516-1521
Molecular imaging by small-animal PET is an important noninvasive means to phenotype transgenic mouse models in vivo. When investigating pathologies of the left ventricular (LV) myocardium, the serial assessment of LV volumes is important. By this, the presence of LV dilation as a sign of developing heart failure can be detected. Whereas PET is usually used to derive biochemical and molecular information, functional parameters such as ventricular volumes are generally measured using echocardiography or MRI. In this study, a novel method to monitor LV dilation in mice with PET is presented and evaluated using cardiac MRI. METHODS: A semiautomatic 3-dimensional algorithm was used to delineate the LV myocardial wall on static PET images depicting myocardial glucose metabolism ((18)F-FDG PET) for 20 mice: 10 wild-type and 10 genetically modified littermates designed to develop a dilative cardiomyopathy phenotype (cardiomyocyte-specific knockout of survivin). The volume enclosed by the 3-dimensional midmyocardial contour was calculated as a measure for LV volume for each mouse. Data were compared with ventricular volumes measured by MRI in the same animals. RESULTS: LV volumes obtained by PET and MRI correlated well (R = 0.89) for hearts with small and large left ventricles. In accordance with the hypothesis, the LV volumes were increased significantly for transgenic mice examined at an older age compared with those examined at a younger age (MRI: 160.5 +/- 25.7 microL vs. 114.7 +/- 15.2 microL [P = 0.012]; PET: 129.3 +/- 15.3 microL vs. 73.8 +/- 15.0 microL [P < 0.001], all values shown as mean +/- SD; for MRI, mean of end-diastolic and end-systolic volumes are given), whereas they did not for their wild-type littermates (MRI: 106.2 +/- 12.3 microL vs. 94.7 +/- 14.6 microL [P = 0.214]; PET: 82.6 +/- 20.9 microL vs. 65.0 +/- 16.9 microL [P = 0.185]). CONCLUSION: Evaluation and quantitation of LV dilation in both control and cardiomyopathic mice can be reliably and serially performed using small-animal PET and (18)F-FDG, yielding useful functional information in addition to metabolic data. 相似文献
254.
255.
Reoperations for fractures of the proximal femur 总被引:1,自引:0,他引:1
P Lüthje 《Annales chirurgiae et gynaecologiae》1986,75(6):337-340
The number and type of reoperations after fractures of the proximal femur was studied in Jokilaakso Regional Hospital, Finland, from 1970 to 1981. Reoperations after fractures of the femoral neck occurred in 32% (24/74), in trochanteric fractures in 13% (6/48). In fractures of the femoral neck 38% (9/24) of the reoperations were performed during the first postoperative year, in trochanteric fractures half of the cases. The average time of hospital stay for reoperation was 19 days. 相似文献
256.
Thomas Küpper 《Wiener Medizinische Wochenschrift》2005,155(7-8):163-170
257.
Bone morphogenetic proteins (BMPs) are bone growth factors, which regulate bone formation during fetal development and bone repair after injury in postfetal life. Since 1992 BMP-7 has been produced by recombinant technique (rhBMP-7). Numerous animal models and clinical trials have shown that rhBMP-7 can induce de novo bone formation in segmental defects of bones and in cases of nonunion. Since 2001 rhBMP-7 has been approved for treatment of tibial nonunion in Europe. The effect of rhBMP-7 is comparable to the clinical and radiological results achieved with bone autografts. The problem of donor site morbidity (which occurs in up to 20% of all cases) is eliminated by the use of BMP-7. Long-term results and experience in clinical practice are not yet available. 相似文献
258.
Abstract Kyphoplasty and vertebroplasty have become recognized procedures for the treatment of vertebral fractures, especially in patients
with osteoporosis. In most cases of osteoporotic spinal vertebral fracture in elderly patients, polymethylmethacrylate (PMMA)
cement is used to fill the defect and stabilize the vertebral body. The techniques of vertebroplasty and kyphoplasty differ
in the possibility of realignment and reconstruction of the vertebral body and spinal column. Long-term results in terms of
integration of the cement and bioreactivity of the vertebral body are still lacking; so, these procedures are still no options
in the treatment of younger patients. Vertebroplasty and kyphoplasty show different success in the management of fresh traumatic
spine fractures. The acute traumatic vertebral fracture has to be classified sensitively, to find the right indication for
cement augmentation. Mild acute compression fractures can be treated by vertebroplasty or kyphoplasty, severe compression
and burst fractures by combination of internal fixation and kyphoplasty. The indications for use of biological or osteoinductive
cement in spinal fracture management must still be regarded as restricted owing to the lack of basic biomechanical research
data. Such cement should not be used except in clinical studies. 相似文献
259.
260.